Follow The Filings

CGEN Compugen

Compugen earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CGEN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CGEN insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $118K sold by 2 insiders under 10b5-1 plans
  1. Zurit Levine SVP, Business Development
    Planned sale
    $4,688 1,875 shares at $2.50 6% of stake
    Traded Jul 9 Filed Jul 13
  2. Zurit Levine SVP, Business Development
    Planned sale
    $6,400 2,000 shares at $3.20 6.4% of stake
    Traded Apr 24 Filed Apr 27
  3. Eran Ophir CEO
    Planned sale
    $16K 5,000 shares at $3.20 31% of stake
    Traded Apr 24 Filed Apr 27
  4. Eran Ophir CEO
    Planned sale
    $15K 5,000 shares at $2.90 31% of stake
    Traded Apr 14 Filed Apr 15
  5. Zurit Levine SVP, Business Development
    Planned sale
    $5,600 2,000 shares at $2.80 6.4% of stake
    Traded Apr 14 Filed Apr 15
  6. Zurit Levine SVP, Business Development
    Planned sale
    $8,013 3,125 shares at $2.56 9.6% of stake
    Traded Apr 10 Filed Apr 15
  7. Zurit Levine SVP, Business Development
    Planned sale
    $19K 7,875 shares at $2.38 21% of stake
    Traded Apr 7–8 Filed Apr 9
  8. Zurit Levine SVP, Business Development
    Planned sale
    $7,700 3,500 shares at $2.20 11% of stake
    Traded Apr 1 Filed Apr 3
  9. Eran Ophir CEO
    Planned sale
    $12K 5,625 shares at $2.21 33% of stake
    Traded Apr 1 Filed Apr 3
  10. Zurit Levine SVP, Business Development
    Planned sale
    $24K 11,875 shares at $2.04 29% of stake
    Traded Mar 26 Filed Mar 30

Also filed in the last 12 months, not counted as buying or selling: 14 option exercises and 9 stock grants.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
6-K
6-K
6-K
6-K ZK2635352
6-K
20-F
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
20-F

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.